Dr. Johnson is an inventor, entrepreneur and expert in single-cell immunology, with a track record of bringing new medical technologies to market. At GigaGen, he has led the development of an industry-leading single-cell technology platform that has quickly established a robust pipeline of antibody therapeutics. Before GigaGen, Dr. Johnson was among the founding members and COO of Natera (NASDAQ: NTRA), where he was responsible for all clinical operations and clinical product development. Prior to Natera he was the ENCODE Project Director at the Stanford Human Genome Center. Dr. Johnson holds a BS in Biology from Duke University, a Ph.D. in Genetics from Stanford University and an MBA from the Haas School of Business at the University of California, Berkeley.
.svg)
